Highlights

Identified two miRNAs capable of stopping the progression of rhabdomyosarcoma

VHIR News

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters…..

Read the full article

Genes may cause some people to develop severe forms of COVID-19

El País

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Multidisciplinary research opens the door to the development of new therapeutic approaches in Parkinson’s disease

Infosalus

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

A Vall d’Hebron study shows that 70% of residents and 56% of staff infected with SARS-CoV-2 in nursing homes are asymptomatic

Beteve

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article View more

Identified two miRNAs capable of stopping the progression of rhabdomyosarcoma

VHIR News

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Genes may cause some people to develop severe forms of COVID-19

El País

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Multidisciplinary research opens the door to the development of new therapeutic approaches in Parkinson’s disease

Infosalus

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

A Vall d’Hebron study shows that 70% of residents and 56% of staff infected with SARS-CoV-2 in nursing homes are asymptomatic

Beteve

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Identified two miRNAs capable of stopping the progression of rhabdomyosarcoma

VHIR News

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Genes may cause some people to develop severe forms of COVID-19

El País

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Multidisciplinary research opens the door to the development of new therapeutic approaches in Parkinson’s disease

Infosalus

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

A Vall d’Hebron study shows that 70% of residents and 56% of staff infected with SARS-CoV-2 in nursing homes are asymptomatic

Beteve

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Identified two miRNAs capable of stopping the progression of rhabdomyosarcoma

VHIR News

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Genes may cause some people to develop severe forms of COVID-19

El País

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Multidisciplinary research opens the door to the development of new therapeutic approaches in Parkinson’s disease

Infosalus

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

A Vall d’Hebron study shows that 70% of residents and 56% of staff infected with SARS-CoV-2 in nursing homes are asymptomatic

Beteve

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Identified two miRNAs capable of stopping the progression of rhabdomyosarcoma

VHIR News

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Genes may cause some people to develop severe forms of COVID-19

El País

El Dr. Josep Roma, investigador principal del grup de Recerca Translacional en Càncer en la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR), ha liderat un estudi per identificar noves dianes terapèutiques que permetin aturar la progressió del rabdomiosarcoma. Es tracta d’un estudi en què han participat els serveis d’Oncologia i Hematologia Pediàtriques, Cirurgia Pediàtrica i Anatomia Patològica de l’Hospital Vall d’Hebron i que ha estat publicat a Cancer Letters.

Read the full article

Research areas

Oncology

In 2020, the Area has been composed by eight groups addressing main unsolved issues in cancer, covering the fields of child and adolescent cancer, melanoma, gynecology, urology, cancer stem cells and molecular mechanisms of the tumor pathologies, as well nanomedicine. We work in close collaboration with the corresponding departments at the Hospital. This provides a unique opportunity to tackle the abovementioned pathologies during the entire course of the disease, from diagnosis (a focus and strength of our Area) to personalized treatment (gathering important international impact during 2020 in the field of child cancer). Our research in 2020 has been relevant also in the field of the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics. Despite, the COVID-19 pandemic, the Area has kept active at virtual shared activities and ONCO-VHIR seminars and the organization of the World Cancer Day event to get closer to the society. During 2020 in-Campus collaborations with VHIO have been strengthen and internalization of our research has been amplified. It is also noteworthy the shared scientific production in terms of publications between different groups of the Area and the stable collaborations between groups that have consolidated during these period.!!

173

PUBLICATIONS

926

IMPACT FACTOR

5.32

AVERAGE IMPACT FACTOR

Vascular Biology and Metabolism (VAM)

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Neurosciences

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Infectious Diseases

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Digestive and Liver Diseases / Nursing

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Immunomediated Diseases and Innovative Therapies

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Research in Surgery

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Obstetrics, Pediatrics and Genetics

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

281

PUBLICATIONS

1353

IMPACT FACTOR

4.81

AVERAGE IMPACT FACTOR

Our Key Figures

1828

TOTAL STAFF

962

RESEARCH STAFF

1641

NUMBER OF
PUBLICATIONS

11375

TOTAL IMPACT
FACTOR

59

PUBLICATIONS
IN Q1

150

PROJECTS & HR GRANTS

17

GRANTS FUNDING

1439

ACTIVE CLINICAL TRIALS

2872

NEW PATIENT INCLUSION

4

SPIN-OFFS/START-UPS
APPROVED

4

LICENSED PATENTS

2

REVENUE FROM
INNOVATION